Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura (ITP) Clinical Trial

Official title:
Prospective Open-Label Study of the Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate whether Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution is an effective and safe treatment in patients with chronic idiopathic thrombocytopenic purpura.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Immune Thrombocytopenic Purpura (ITP)
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic

Clinical Trial Details

NCT number	NCT00162006
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 2
Start date	January 13, 2003
Completion date	December 3, 2003

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03524612` - A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP	Phase 2
Completed	`NCT01713738` - Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)	Phase 1/Phase 2
Completed	`NCT00157079` - Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders	Phase 3
Recruiting	`NCT02877212` - Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients	Phase 3
Terminated	`NCT03866577` - Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients	Phase 1/Phase 2